Systemic Therapies for the Management of Advanced and Metastatic Gastric and Gastroesophageal Cancers: Agents and Regimens
Johanna C. Bendell S.B., MD
Associate Director of Drug Development and Director of GI Cancer Research
Sarah Cannon Research Institute
This infographic enduring activity will cover the diagnosis, treatment and management of patients with advanced and metastatic gastric and gastroesophageal cancers.
This activity is designed to educate oncologists, oncology nurses and other health care providers involved in the care of patients with advanced/metastatic gastric cancer and gastroesophageal junction adenocarcinoma.
Upon completion of the program, attendees should be able to:
- Describe the tissue changes characteristic of gastric and gastroesophageal cancers
- Review clinical trial data on the efficacy and safety of systemic treatment options across all lines of therapy for patients with advanced and metastatic gastric and gastroesophageal junction cancers
- Discuss guideline-recommended therapeutic regimens across all lines of treatment for patients with advanced and metastatic gastric and gastroesophageal junction cancer
ACCREDITATION AND DESIGNATION STATEMENTS
Med Learning Group is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
Credit Designation Statement
Med Learning Group designates this enduring activity for a maximum of 1.0 AMA Category 1 Credit(s)TM. Physicians should claim only the credit commensurate with the extent of their participation in the enduring activity.
Nursing Credit Information
Purpose: This program would be beneficial for nurses involved in the care of patients with gastric and gastroesophageal cancers. Credits: 1.0 ANCC Contact Hour(s)
Ultimate Medical Academy/CCM is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation. Awarded 1.0 contact hour(s) of continuing nursing education of RNs and APNs.
DISCLOSURE POLICY STATEMENT
In accordance with the Accreditation Council for Continuing Medical Education (ACCME) Standards for Commercial Support, educational programs sponsored by Med Learning Group must demonstrate balance, independence, objectivity, and scientific rigor. All faculty, authors, editors, staff, and planning committee members participating in a MLG-sponsored activity are required to disclose any relevant financial interest or other relationship with the manufacturer(s) of any commercial product(s) and/or provider(s) of commercial services that are discussed in an educational activity.
DISCLOSURE OF FINANCIAL RELATIONSHIPS
Dr. Bendell has received contracted research funding for clinical trials from the following: Gilead, Genentech, BMS, Five Prime, Lilly, Merck, MedImmune, Celgene, EMD Serono, Taiho, Macrogenics, GSK, Novartis, OncoMed, LEAP, TG Therapeutics, Astrazeneca, BI, Daiichi Sankyo, Bayer, Incyte, Apexigen, Roche, Koltan, SynDevRx, Forty Seven, Abbvie, StemCentrix, Array, Onyx, Sanofi, Takeda, Abbott, Eisai, Celldex, Agios, CytoMx, Nektar, ARMO, Boston Biomedical, Ipsen, Merrimack, Novartis, Tarveda, Tyrogenex, Oncogenex, Marshall Edwards, Pieris, Mersana, Calithera, Blueprint, Gritstone, Evelo, FORMA, Forty Seven, EMD Serono, Merus, Jacobio, Blueprint, Effector, Novocure, Sorrento, Arrys, and Tracon.
CME Content Review
The content of this activity was independently peer reviewed.
The reviewer of this activity has nothing to disclose.
CNE Content Review
The content of this activity was peer reviewed by a nurse reviewer.
The reviewer of this activity has nothing to disclose.
Staff, Planners and Managers
Matthew Frese, General Manager of Med Learning Group has nothing to disclose.
Christina Gallo, SVP, Educational Development for Med Learning Group has nothing to disclose.
Ana Goffin, MPA, Program Manager for Med Learning Group has nothing to disclose.
Nina K. Oshio, Pharma D, Medical Director, Scientific and Medical Services for Med Learning Group has nothing to disclose.
Lauren Welch, MA, VP, Outcomes and Accreditation for Med Learning Group has nothing to disclose.
DISCLOSURE OF UNLABELED USE
Med Learning Group requires that faculty participating in any CME/CNE activity disclose to the audience when discussing any unlabeled or investigational use of any commercial product or device not yet approved for use in the United States.
During the course of this lecture, the faculty may mention the use of medications for both FDA-approved and non-approved indications.
METHOD OF PARTICIPATION
There are no fees for participating and receiving CME credit for this enduring activity. To receive CME/CNE credit participants must:
1. Read the CME/CNE information and faculty disclosures;
2. Participate in the enduring activity; and
3. Complete pre-and-post surveys and evaluation.
You will receive your certificate as a downloadable file.
Med Learning Group makes every effort to develop CME activities that are scientifically based. This activity is designed for educational purposes. Participants have a responsibility to utilize this information to enhance their professional development in an effort to improve patient outcomes. Conclusions drawn by the participants should be derived from careful consideration of all available scientific information. The participant should use his/her clinical judgment, knowledge, experience, and diagnostic decision-making before applying any information, whether provided here or by others, for any professional use.
For CME questions, please contact: Med Learning Group at firstname.lastname@example.org.
Contact this CME provider at Med Learning Group for privacy and confidentiality policy statement information at: http://www.medlearninggroup.com/privacy-policy/
RELEASE DATE: October 12, 2018
EXPIRATION DATE: October 12, 2019
Copyright © 2018 Med Learning Group. All rights reserved. These materials may be used for personal use only. Any rebroadcast, distribution, or reuse of this presentation or any part of it in any form for other than personal use without the express written permission of Med Learning Group is prohibited.